SecBot SecBot
Biotech Drug Report Generated Sep 5, 2026

INS1033

INSM·INSMED Inc
NEUTRAL
Drug Impact Rating1/10
Trial phase
Not stated
Time to market
Not stated
Why 1/10
No scheduled catalyst exists for "INS1033" because the drug is not identifiable in any public source. ImpactScore is 1, the minimum, reflecting the absence of any known binary catalyst, clinical data, or regulatory milestone tied to this name.
Actionable Insight NEUTRAL

There is no actionable information on "INS1033", it is not a known Insmed pipeline asset. Investors should monitor Insmed's corporate presentations and pipeline page for any new early-stage candidates, but no catalyst related to this drug name can be identified.

Price Chart

Loading chart...

Executive Summary

"INS1033" does not appear in any publicly available database, clinical trial registry, SEC filing, press release, or Insmed pipeline disclosure. Insmed Incorporated (Nasdaq: INSM) is a real biopharmaceutical company with approved product Arikayce and late-stage candidates brensocatib (BRINSUPRI, approved in Japan for NCFB) and treprostinil palmitil (TPIP, Phase 3 completed for PH-ILD). However, no drug candidate designated "INS1033" has been identified in any source. The drug name may be a preclinical internal code not yet publicly disclosed, a typo, or a non-existent identifier.

How It Works

Unknown. No mechanism information is publicly available for a drug designated "INS1033."

Trial Status

No clinical trials, FDA records, or pipeline disclosures referencing "INS1033" were found in any public or internal database. Insmed's known pipeline consists of Arikayce (approved), brensocatib (approved in Japan, Phase 2 completed/terminated in other indications), and treprostinil palmitil (Phase 3 completed).

The Two-Sided Case

▲ Bull Case3
Insmed (INSM) is a well-capitalized biopharma with an approved product (Arikayce) and strong analyst consensus: 29 Buy/Strong Buy ratings vs 1 Hold, with a mean price target of ~$200.
Institutional ownership is deep, FMR LLC ($1.7B), BlackRock ($1.7B), and Vanguard ($1.1B) are top holders as of Q2 2026 (per institutional holdings data).
Brensocatib (BRINSUPRI) recently received Japanese approval for NCFB, and the pipeline includes treprostinil palmitil in Phase 3 for PH-ILD.
▼ Bear Case3
'INS1033' is not a known Insmed pipeline asset, there is zero public information about this drug candidate, making it impossible to evaluate.
Insmed's stock has declined from a 52-week high of ~$213 to ~$126 (per stock price data), and short interest was ~5% of outstanding shares as of mid-August 2026.
The brensocatib Phase 2 CEDAR study in hidradenitis suppurativa was terminated, and the stock saw negative price reactions around prior clinical catalysts.

Upcoming Catalysts

  • None identifiable for INS1033. For Insmed broadly: potential brensocatib U.S. FDA decision and TPIP data readouts.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

INSMED Inc 8-K INSM ·Originating report

Sources · 2

Hover a chip for the title
1 sec.gov2 prnewswire.com